Costs and outcomes of liver transplantation in adults - A prospective, 1-year, follow-up study

被引:26
作者
Rufat, P
Fourquet, F
Conti, F
Le Gales, C
Houssin, D
Coste, J
机构
[1] Hop Cochin, Dept Biostat & Informat Med, F-75674 Paris 14, France
[2] Hop Cochin, Serv Chirurg, F-75674 Paris 14, France
[3] Hop Bicetre, INSERM, U357, F-94276 Le Kremlin Bicetre, France
关键词
D O I
10.1097/00007890-199907150-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Orthotopic liver transplantation (OLT) is widely used to treat patients with end-stage liver disease. However, data on the cost of the procedure are fragmentary. We evaluated the costs, as calculated from resource use, and outcomes of OLT in adults, from registration on the transplant waiting list to the end of the 1st-year of follow-up after the transplant. Methods. Two parallel cohort studies were conducted from 1994 to 95. All patients ages 18 years and older, on the waiting list (n=33) according to national criteria or having undergone transplants (n=38) were followed for 1 year or until either the transplant (waiting list cohort) or death (waiting list and transplantation cohorts). Results. Eighty percent of the patients undergoing transplants were alive after 1 year, and no patient died while on the waiting list. However, the estimated cost of the procedure was high: more than pound 55,000 for the 1st year after OLT, to be added to pound 5,500 for evaluation and further costs motivated by the planned transplant during an average 6.5 months on the waiting list. Age over 40 and a baseline Child-Pugh score of 10 and over were predictive of high costs. The proportion of costs associated with immunosuppressive therapy and rejection were very high. Conclusions. This medical and economic cohort study suggests that OLT is still expensive; the study identifies sources of extra cost that could be limited either by improved selection of patients or, in the future, by technological advances in immunosuppressive therapy that help avoid medical complications. It also suggests the situation is precarious, with outcomes and costs being very sensitive to variation in graft availability.
引用
收藏
页码:76 / 83
页数:8
相关论文
共 38 条
[21]  
Karnofsky DA., 1949, CLIN EVALUATION CHEM, P196
[22]  
Kemper R R, 1997, Liver Transpl Surg, V3, P513, DOI 10.1002/lt.500030506
[23]   THE IMPACT OF IMMUNOSUPPRESSIVE REGIMENS ON THE COST OF LIVER-TRANSPLANTATION - RESULTS FROM THE US FK506 MULTICENTER TRIAL [J].
LAKE, JR ;
GORMAN, KJ ;
ESQUIVEL, CO ;
WIESNER, RH ;
KLINTMALM, GB ;
MILLER, CM ;
SHAW, BW ;
GORDON, JA .
TRANSPLANTATION, 1995, 60 (10) :1089-1095
[24]  
Lucey M R, 1997, Liver Transpl Surg, V3, P628
[25]   ANALYSIS OF SERIAL MEASUREMENTS IN MEDICAL-RESEARCH [J].
MATTHEWS, JNS ;
ALTMAN, DG ;
CAMPBELL, MJ ;
ROYSTON, P .
BRITISH MEDICAL JOURNAL, 1990, 300 (6719) :230-235
[26]   THE NEED FOR LIVER-TRANSPLANTATION - A NATIONWIDE ESTIMATE BASED ON CONSENSUS REVIEW [J].
MODAN, B ;
SHPILBERG, O ;
BARUCH, Y ;
SIKULER, E ;
ANIS, E ;
ASHUR, Y ;
CHETRIT, A ;
LUXENBURG, O ;
ROSENBERG, E ;
ROSENTHOL, N ;
SADETZKI, S ;
BENAIM, H ;
ECKSTEIN, H ;
SHOUVAL, D .
LANCET, 1995, 346 (8976) :660-662
[27]   SHOULD ALCOHOLICS COMPETE EQUALLY FOR LIVER-TRANSPLANTATION [J].
MOSS, AH ;
SIEGLER, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1295-1298
[28]   Clinical economics review: Liver transplantation [J].
OGrady, JG .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (03) :445-451
[29]  
Payne JL, 1996, AM SURGEON, V62, P320
[30]   Organ transplant waiting-list in France [J].
Romano, P ;
Boutin, B ;
Houssin, D .
LANCET, 1997, 350 (9074) :372-372